Pulmonary Arterial Hypertension (PAH) is a rare and progressive disorder characterized by high blood pressure in the arteries of the lungs due to the narrowing of these blood vessels. This condition leads to increased workload on the heart, eventually resulting in heart failure. The PAH market has witnessed significant growth in recent years due to advancements in treatment options, increasing awareness, and a rise in the prevalence of PAH worldwide.
Get a Sample PDF copy of the report @ https://www.reportsinsights.com/sample/665044
Pulmonary Arterial Hypertension (PAH) is defined as a mean pulmonary artery pressure (mPAP) of ≥25 mmHg at rest, confirmed by right heart catheterization. PAH falls under Group 1 of the World Health Organization (WHO) classification of pulmonary hypertension and is associated with idiopathic, hereditary, drug-induced, and connective tissue diseases.
The PAH market is segmented based on drug class, route of administration, distribution channel, and region.
Endothelin Receptor Antagonists (ERAs) (Bosentan, Ambrisentan, Macitentan)
Phosphodiesterase-5 Inhibitors (PDE-5 inhibitors) (Sildenafil, Tadalafil)
Prostacyclin and Prostacyclin Analogs (Epoprostenol, Treprostinil, Iloprost)
Soluble Guanylate Cyclase (sGC) Stimulators (Riociguat)
Calcium Channel Blockers (Nifedipine, Diltiazem)
Oral
Intravenous
Subcutaneous
Inhalation
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
The PAH market is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 5.8% from 2024 to 2032. The market growth is driven by increasing research and development (R&D) investments, improved drug therapies, and the rising prevalence of risk factors such as connective tissue disorders, HIV infections, and congenital heart diseases.
The incidence of PAH is increasing globally due to lifestyle changes, rising obesity rates, and genetic predisposition.
The introduction of novel therapies, including combination treatments and gene therapy approaches, has improved patient survival rates and quality of life.
Growing awareness about PAH through government initiatives, medical organizations, and patient advocacy groups has contributed to early diagnosis and better treatment outcomes.
The aging population is at higher risk for PAH, leading to an increased demand for effective treatment options.
Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.reportsinsights.com/industry-forecast/pulmonary-arterial-hypertension-market-statistical-analysis-665044
PAH medications and therapies are expensive, posing a significant financial burden on patients and healthcare systems.
While awareness is increasing in developed countries, many patients in developing regions remain undiagnosed or receive inadequate treatment.
Many PAH drugs have severe side effects, including liver toxicity, hypotension, and gastrointestinal issues, which can limit their adoption.
Hospitals and specialized clinics provide PAH diagnosis, treatment, and management services, making them a key application area for PAH drugs and therapies.
Dedicated PAH treatment centers offer specialized care with advanced diagnostic and therapeutic facilities.
Patients with stable PAH conditions often receive long-term treatment at home through oral or inhalation therapies, increasing the demand for homecare-based PAH management.